Novartis secures speedy FDA review for sickle cell drug
JNJ beats on earnings
Roche’s Genentech goes on deal spree
Eyes on Oklahoma as JNJ awaits $17bn opioid case verdict
*scroll through previous pages at the bottom to get older news*
Want to stay updated on CP happenings? New features, new boards, CP wire articles, and more? Click here to subscribe
